Latest Breaking News On - Transarterial chemoembolization - Page 1 : comparemela.com

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

Tyrosine-kinase-inhibitors
Unresectable-hepatocellular-carcinoma
Hepatocellular-carcinoma
Hcc
Dotace
Transarterial-chemoembolization
Lenvatinib
Launch-study
Emerald-1-study
Durvalumab
Bevacizumab

DOH CL advocates healthy habits to safeguard against liver cancer

DOH CL advocates healthy habits to safeguard against liver cancer
punto.com.ph - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from punto.com.ph Daily Mail and Mail on Sunday newspapers.

Philippines
Balanga
Batangas
Filipinos
Transarterial-chemoembolization
Transarterial-radioembolization
Agnes-alipio
Rickp-quiambao
Health-development-non
Communicable-disease-cluster-senior-health-program
Central-luzon-center
Department-of-health-central-luzon-center

Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

Italy
Japan
Riccardo-lencioni
Department-of-surgery
Critical-area-pathology
Druvalumab-and-bevacizumab-plus-tace
Dotace
Hcc
Hepatocellular-carcinoma
Gastrointestinal-cancer
Gi-cancer
Asco-gi

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial

IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China
Sweden
Cambridge
Cambridgeshire
United-kingdom
Italy
Canada
Australia
Kunlun
Zhejiang
Japan
United-states

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial | Antibodies

Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial

China
London
City-of
United-kingdom
Canada
Kunlun
Zhejiang
South-korea
Cambridge
Cambridgeshire
Italy
Sweden